BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), , a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announced the publication of the mechanism ...
IMNN-001 continues to show a favorable safety profile.
GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients Second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback